Physician profile
Niloufar Ghadiri
NPI 1629159652
$9,116.87
in general payments reported to CMS, 2019-2025
41 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,032 · 2020: $904 · 2021: $978 · 2022: $947 · 2023: $1,713 · 2024: $1,223 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,759.93 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $929.04 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $768.70 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $728.13 | 2019-2025 | |
| Lilly USA, LLC | $721.79 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $451.70 | 2019-2025 | Lagevrio, Verquvo, Capvaxive |
| Abbvie INC. | $401.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $358.85 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $326.83 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $301.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.24 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $273.59 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $177.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $169.02 | 2019-2022 | |
| Allergan, INC. | $163.22 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niloufar Ghadiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.